NCT02210065View on ClinicalTrials.gov

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 3, 2015

Primary Completion Date

May 13, 2019

Study Completion Date

May 13, 2019

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)

CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Miltenyi Biotec B.V. & Co. KG

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02210065 - Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation | Biotech Hunter | Biotech Hunter